UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
|
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Item 8.01 |
Other Events. |
On June 22, 2020, Principia Biopharma Inc. (the “Company”) issued a press release announcing that its partner Genzyme Corporation (“Sanofi”) had enrolled the first patient in Sanofi’s Phase 3 clinical trial of SAR442168, formerly known as PRN2246, in patients with relapsing multiple sclerosis. Pursuant to the License Agreement by and between the Company and Sanofi dated as of November 8, 2017, and as amended on May 24, 2018, upon dosing of the first patient, Principia will be entitled to a $50.0 million milestone payment from Sanofi.
A copy of this press release is attached as Exhibit 99.1 hereto.
Item 9.01Financial Statements and Exhibits.
|
Exhibit Number |
|
Description |
|
99.1
|
|
Press Release issued by Principia Biopharma Inc. dated June 22, 2020 |
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PRINCIPIA BIOPHARMA INC.
|
|
|
|
|
|
By: |
/s/ Roy Hardiman |
|
|
Roy Hardiman |
|
|
Chief Business Officer |
Dated: June 26, 2020
|
|
|
|
|
|
|
|
|
|
|
|